cihr_grants: 170663
This data as json
| external_id | title | project_lead_name | co_researchers | institution | province | country | competition_year | award_amount | program | program_type | theme | research_subject | keywords | abstract | duration | source_url |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170663 | Control of cell proliferation and survival. | Litchfield David W | Litchfield, David W | Western University (Ontario) | Ontario | Canada | 200809 | 622698.0 | Operating Grant | Operating Grants | Biomedical | Cancer Research | Apoptosis; Caspase; Cell Survival; Protein Kinase; Signal Transduction | The recent success of Gleevec (imatinib) which targets the BCR-Abl protein kinase for the treatment of chronic myelogenous leukemia provides proof-of-principle for molecular-targeted therapy directed against a protein kinase. Spurred by the success of Gleevec, this research project is focused on a close relative of BCR-Abl known as protein kinase CK2 that is present at abnormally high levels in many tumours and that causes cancer when its levels are increased in mice. We want to determine how CK2 allows cancer cells to acquire enhanced survival as compared to normal cells so that this information can be used to devise molecular-targeted therapies directed at the precise defects that underlie the disease. Over the past several years, our group has performed extensive research on the CK2 group of protein kinases with studies focused on defining how CK2 is regulated in cells and defining how CK2 is involved in the control of cell growth and survival. To capitalize on our expertise, we will use knowledge of the three-dimensional structure of CK2 together with computational and experimental approaches to determine how CK2 modulates the regulatory networks that control cell survival. By understanding how CK2 promotes the survival of cancer cells, we envisage that it will be possible to devise novel CK2-targeted therapies that will be effective for those forms of cancer or leukemia that are characterized by increased levels of CK2. | 5 yrs 0 mth | https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=170663&lang=en |